We will help our partners prevail in their mission to develop needed therapies. We will ensure that high-quality development and imperative urgency remains our focus.
How We Help
In The News
Launch Therapeutics partners with Opthea to advance OPT-302, a promising therapy for wet AMD
Opthea Secures up to US$170 Million in Non-Dilutive Financing for OPT-302 in wet AMD
Melbourne, Australia and Boston, MA, USA; 15 August, 2022–Opthea Limited (ASX:OPT; NASDAQ: OPT), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced a non-dilutive financing transaction for up to US$170 million (AU$240 million) from investment funds working with Launch Therapeutics (Launch Tx) to finance and advance the ongoing Phase 3 clinical trials and pre-commercialization activities of OPT-302 for wet age-related macular degeneration (wet AMD). Launch Tx is the recently formed development company backed by funds managed by global investment firm Carlyle (NASDAQ: CG) and its life sciences franchise, Abingworth.